My Cart Find A Store

Nutritional Supplement

Borage Oil

Possible Deficiencies

Many people in Western societies may be at least partially GLA-deficient as a result of aging, glucose intolerance, dietary fat intake, and other problems, though the exact incidence of deficiency remains unknown. People with deficiencies benefit from supplemental GLA intake from borage oil, black currant seed oil, or evening primrose oil.

Those with premenstrual syndrome,19diabetes,20 scleroderma,21 Sjogren’s syndrome,22tardive dyskinesia,23eczema,24 and other skin conditions25 may have a metabolic block that interferes with the body’s ability to make GLA. However, most clinical trials supplementing GLA for these conditions has used evening primrose oil, and not borage oil.

Side Effects

Borageseeds contain small amounts of liver toxins called pyrrolizidine alkaloids (PA). However, testing has not demonstrated the presence of the alkaloid in the seed oil.26 Most commercially available borage seed oil is, therefore, likely to be PA-free and presents no risk of PA toxicity. Minor side effects from borage oil use can include bloating, nausea, indigestion, and headache.27

References

1. Wren RC. Potter's New Cyclopedia of Botanical Drugs and Preparations. Essex, England: C.W. Daniel and Co., 1988, 41.

2. Pullman-Mooar S, Laposata M, Lem D, et al. Alteration of the cellular fatty acid profile and the production of eicosanoids in human monocytes by gamma-linolenic acid. Arthritis Rheum 1990;33:1526-33.

3. Leventhal LJ, Boyce EG, Zurier RB. Treatment of rheumatoid arthritis with gammalinolenic acid. Ann Intern Med 1993;119:867-73.

4. Zurier RB, Rossetti RG, Jacobson EW, et al. Gamma-linolenic acid treatment of rheumatoid arthritis. A randomized, placebo-controlled trial. Arthritis Rheum 1996;39:1808-17.

5. Leventahn LJ, Boyce EG, Zuerier RB. Treatment of rheumatoid arthritis with black currant seed oil. Br J Rheumatol 1994;33:847-52.

6. Brzeski M, Madhok R, Capell HA. Evening primrose oil in patients with rheumatoid arthritis and side­effects of non­steroidal anti­inflammatory drugs. Brit J Rheumatol 1991;30:370-2.

7. Jantti J, Seppala E, Vapaatalo H, Isomaki H. Evening primrose oil and olive oil in treatment of rheumatoid arthritis. Clin Rheumatol 1989;8:238-44.

8. Belch JJ, Ansell D, Madhok R, et al. Effects of altering dietary essential fatty acids on requirements for non­steroidal anti­inflammatory drugs in patients with rheumatoid arthritis: a double blind placebo controlled study. Ann Rheum Dis 1988;47:96-104.

9. Schirmer MA, Phinney SD. Gamma-linolenate reduces weight regain in formerly obese humans. J Nutr 2007;137:1430-35.

10. Navarro-Herrera D, Aranaz P, Eder-Azanza L, et al. Borago officinalis seed oil (BSO), a natural source of omega-6 fatty acids, attenuates fat accumulation by activating peroxisomal beta-oxidation both in C. elegans and in diet-induced obese rats. Food Funct 2018 Aug;9(8):4340–51.

11. Tollesson A, Frithz A, Berg A, Karlman G. Essential fatty acids in infantile seborrheic dermatitis. J Am Acad Dermatol 1993;28:957-61.

12. Tollesson A, Frithz A. Borage oil, an effective new treatment for infantile seborrheic dermatitis. Br J Dermatol 1993;129:95 [letter].

13. Tollesson A, Frithz A, Berg A, Karlman G. Essential fatty acids in infantile seborrheic dermatitis. J Am Acad Dermatol 1993;28:957-61.

14. Tollesson A, Frithz A. Borage oil, an effective new treatment for infantile seborrheic dermatitis. Br J Dermatol 1993;129:95 [letter].

15. Leventhal LJ, Boyce EG, Zurier RB. Treatment of rheumatoid arthritis with gammalinolenic acid. Ann Intern Med 1993;119:867-73.

16. Zurier RB, Rossetti RG, Jacobson EW, et al. Gamma-linolenic acid treatment of rheumatoid arthritis. A randomized, placebo-controlled trial. Arthritis Rheum 1996;39:1808-17.

17. Landi G. Oral administration of borage oil in atopic dermatitis. J Appl Cosmetology 1993;11:115-20.

18. Tollesson A, Frithz A. Borage oil, an effective new treatment for infantile seborrheic dermatitis. Br J Dermatol 1993;129:95 [letter].

19. Horrobin DF, Manku M, Brush M, et al. Abnormalities in plasma essential fatty acid levels in women with pre-menstrual syndrome and with non-malignant breast disease. J Nutr Med 1991;2:259-64.

20. Keen H, Payan J, Allawi J, et al. Treatment of diabetic neuropathy with gamma-linolenic acid. Diabetes Care 1993;16:8–15.

21. Horrobin DF. Essential fatty acid metabolism in diseases of connective tissue with special reference to scleroderma and to Sjogren's syndrome. Med Hypotheses 1984;14:233-47.

22. Horrobin DF, Campbell A. Sjogren's syndrome and the sicca syndrome: the role of prostaglandin E1 deficiency. Treatment with essential fatty acids and vitamin C. Med Hypotheses 1980;6:225-32.

23. Vaddadi KS, Gilleard CJ. Essential fatty acids, tardive dyskinesia, and schizophrenia. In Omega-6 Essential Fatty Acids: Pathophysiology and Roles in Clinical Medicine. Horrobin DF (ed). New York: Alan R Liss, 1990, 333-43.

24. Manku MS, Horrobin DF, Morse NL, et al. Essential fatty acids in the plasma phospholipids of patients with atopic eczema. Br J Dermatol 1984;110:643-8.

25. Horrobin DF. Essential fatty acids in clinical dermatology. J Am Acad Dermatol 1989;20:1045-53.

26. Parvais O, Vander Stricht B, Vanhaelen-Fastré R,Vanhaelen M. TLC detection of pyrrolizidine alkaloids in oil extracted from the seeds of Borago officinalis. J Planar Chromatography 1994;7:80-2.

27. Awang DVC. Borage. Can Pharm J 1990;123:121-3.

Copyright © 2025 TraceGains, Inc. All rights reserved.

Learn more about TraceGains, the company.

The information presented by TraceGains is for informational purposes only. It is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over the counter medication is also available. Consult your doctor, practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications. Information expires December 2025.